A possible mechanism of impaired NK cytotoxicity in cancer patients: Down-regulation of DAP10 by TGF-β1

Tumori

Volumn 97, Issue 3, 2011, Pages 350-357

  Lee, June Chul ^a   Lee, Kyung Mi ^b   Ahn, Yong Oon ^a   Suh, Beomseok ^a   Heo, Dae Seog ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

DAP10; Human NK cells; NKG2D; TGF ; Tumor immunity

Indexed keywords

BAFILOMYCIN A1; CELL SURFACE PROTEIN; CONCANAMYCIN A; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN DAP10; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DAP10 GENE; DOWN REGULATION; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IMMUNOMODULATION; IMMUNOREGULATION; INTRACELLULAR SIGNALING; LYMPHOCYTE ACTIVATION; MOLECULAR DYNAMICS; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NKG2D GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR GENE; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DOWN-REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROTEIN MODIFICATION, TRANSLATIONAL; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79960849046     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Champsaur M, Lanier LL: Effects of NKG2D ligand expression on host immune responses. Immunol Rev, 235: 267-285, 2010.
2. Gasser S, Raulet DH: Activation and self-tolerance of natural killer cells. Immunol Rev, 214: 130-142, 2006. (Pubitemid 44707907)
3. Coudert JD, Scarpellino L, Gros F, Vivier E, Held W: Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. Blood, 111: 3571-3578, 2008.
4. Perea L, Shao L, Patel A, Evans K, Meresse B, Blumberg R, Geraghty D, Groh V, Spies T, Jabri B, Mayer L: Expression of nonclassical class I molecules by intestinal epithelial cells. Inflamm Bowel Dis, 13: 298-307, 2007. (Pubitemid 46465911)
5. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T: Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol, 2: 255-260, 2001. (Pubitemid 33706003)
6. Kubin M, Cassiano L, Chalupny J, Chin W, Cosman D, Fanslow W, Mullberg J, Rousseau AM, Ulrich D, Armitage R: ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur J Immunol, 31: 1428-1437, 2001. (Pubitemid 32454690)
7. Woan K, Reddy V: Potential therapeutic role of natural killer cells in cancer. Expert Opin Biol Ther, 7: 17-29, 2007. (Pubitemid 46089207)
8. Sutlu T, Alici E: Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med, 266: 154-181, 2009.
9. Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M, Miyazaki M: Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg, 20: 445-451, 2003. (Pubitemid 37116950)
10. Wojtowicz-Praga S: Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs, 21: 21-32, 2003.
11. Jaiswal S, Chao MP, Majeti R, Weissman IL: Macrophage as mediators of tumor immunosurveillance. Trends Immunol 31: 212-219, 2010.
12. Yang L, Pang Y, Moses HL: TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol, 31: 220-227, 2010.
13. Park HY, Wakefield LM, Mamura M: Regulation of tumor immune surveillance and tumor immune subversion by tgf-Beta. Immune Netw, 9: 122-126, 2009.
14. Lee JC, Lee KM, Kim DW, Heo DS: Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol, 172: 7335-7340, 2004.
15. Diefenbach A, Tomasello E, Lucas M, Jamieson AM, Hsia JK, Vivier E, Raulet DH: Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol, 3: 1142-1149, 2002. (Pubitemid 35469698)
16. Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M: NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat Immunol, 3: 1150-1155, 2002. (Pubitemid 35469699)
17. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, Phillips JH: An activating immunoreceptor complex formed by NKG2D and DAP10. Science, 285: 730-732, 1999.
18. Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ: NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol- 3-kinase in human natural killer cells. Nat Immunol, 7: 524-532, 2006.
19. Andre P, Castriconi R, Espeli M, Anfossi N, Juarez T, Hue S, Conway H, Romagne F, Dondero A, Nanni M, Caillat-Zucman S, Raulet DH, Bottino C, Vivier E, Moretta A, Paul P: Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors. Eur J Immunol, 34: 961-971, 2004. (Pubitemid 39255974)
20. Roda-Navarro P, Reyburn HT: The traffic of the NKG2D/DAP10 receptor complex during natural killer (NK) cell activation. J Biol Chem, 284: 16463-16472, 2009.
21. Rosen DB, Araki M, Hamerman JA, Chen T, Yamamura T, Lanier LL: A structural basis for the association of DAP12 with mouse, but not human, NKG2D. J Immunol, 173: 2470-2478, 2004. (Pubitemid 39063104)
22. Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT: TGF-β downregulated the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol, 12: 7-13, 2010.
23. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, Biassoni R, Bottino C, Moretta L, Moretta A: Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A, 100: 4120-4125, 2003. (Pubitemid 36418167)
24. Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y: Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)- ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem, 266: 17707-17712, 1991. (Pubitemid 21907995)
25. Groh V, Wu J, Yee C, Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature, 419: 734-738, 2002. (Pubitemid 35177960)
26. Valitutti S: Immunological synapse: center of attention again. Immunity, 29: 384-386, 2008.
27. Siegel PM, Massague J: Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer, 3: 807-821, 2003.
28. Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 425: 577-584, 2003. (Pubitemid 37280136)
29. Trotta R, Fettucciari K, Azzoni L, Abebe B, Puorro KA, Eisenlohr LC, Perussia B: Differential role of p38 and c-Jun N-terminal kinase 1 mitogen-activated protein kinases in NK cell cytotoxicity. J Immunol, 165: 1782-1789, 2000. (Pubitemid 30643127)
30. Yu TK, Caudell EG, Smid C, Grimm EA: IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. J Immunol, 164: 6244-6251, 2000. (Pubitemid 30408804)
31. Singh RA, Zhang JZ: Differential activation of ERK, p38, and JNK required for Th1 and Th2 deviation in myelin-reactive T cells induced by altered peptide ligand. J Immunol, 173: 7299-7307, 2004. (Pubitemid 39628167)
32. Maliekal TT, Anto RJ, Karunagaran D: Differential activation of Smads in HeLa and SiHa cells that differ in their response to transforming growth factor-beta. J Biol Chem, 279: 36287-36292, 2004. (Pubitemid 39128965)
33. Jeon HS, Jen J: TGF-beta signaling and the role of inhibitory Smads in non-small cell lung cancer. J Thorac Oncol, 5: 417-419, 2010.
34. Xu Y, Pasche B: TGF-beta signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet, 16 (Spec No 1): R4-20, 2007.
35. Brabletz T, Pfeuffer I, Schorr E, Siebelt F, Wirth T, Serfling E: Transforming growth factor beta and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site. Mol Cell Biol, 13: 1155-1162, 1993. (Pubitemid 23040282)
36. Sillett HK, Cruickshank SM, Southgate J, Trejdosiewicz LK: Transforming growth factor-beta promotes 'death by neglect' in post-activated human T cells. Immunology, 102: 310-316, 2001. (Pubitemid 32281158)
37. Letterio JJ: TGF-beta signaling in T cells: roles in lymphoid and epithelial neoplasia. Oncogene, 24: 5701-5712, 2005.
38. Kopp HG, Placke T, Salih HR: Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res, 69: 7775-7783, 2009.